Gilead/Roche Tamiflu Has Two-Thirds Of Flu Market, Gilead Tells BIO
Executive Summary
Tamiflu is garnering about two-thirds of U.S. neuraminidase inhibitor prescriptions as the 1999-2000 flu season winds down, Gilead CEO John Martin, PhD, said Feb. 16 at the Biotechnology Industry Organization CEO and Investor Conference in New York City.
You may also be interested in...
Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg
The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.
Vaccine Challenge Studies Could Shrink Phase III Trials - Aventis' Lindberg
The use of vaccine challenge studies could reduce the size of Phase III trials, Aventis Pasteur Exec VP-Research & Development Alf Lindberg said at the World Vaccine Congress in Paris Sept. 19.
Medeva Fluvirin Production Returns To Market-Demand Level
Production of Medeva's influenza vaccine Fluvirin has returned to levels of market demand following improvements in the manufacturing process, the company said.